You are about to leave the Clinical Value website now.

Cancel

Elecsys PIVKA-II and Elecsys AFP assays demonstrate good clinical performance for hepatocellular carcinoma (HCC) diagnosis across different disease stages and aetiologies

Tags

You May Also Like

Performance evaluation of the Elecsys PIVKA II and Elecsys AFP assays for hepatocellular carcinoma diagnosis
Biomarkers
9 December 2022

Performance evaluation of the Elecsys PIVKA-II and Elecsys AFP assays for hepatocellular carcinoma diagnosis

Prothrombin induced by vitamin K absence-II (PIVKA-II) is a serum biomarker linked to hepatocellular carcinoma (HCC), showing superiority to alpha-fetoprotein (AFP) for early disease detection. This study assesses the clinical…

Read More
Biomarkers
9 December 2022

Analytical performance and method comparison of the Elecsys PIVKA-II immunoassay as an aid in diagnosis of hepatocellular carcinoma (HCC)

This study evaluates the analytical performance of the Elecsys PIVKA-II immunoassay to aid in HCC diagnosis, establish method-specific reference ranges in healthy individuals, and perform a method comparison versus commercially…

Read More
Biomarkers
9 December 2022

Clinical evaluation of Elecsys PIVKA-II for patients with advanced hepatocellular carcinoma

Prothrombin induced by vitamin K absence-II (PIVKA-II) was reported as a diagnosis and prognosis marker for hepatocellular carcinoma (HCC). This prospective study aims to comparatively verify Elecsys PIVKA-II and conventional…

Read More

SHARE

Be the first to receive updates, event opportunities, and thought leadership insights.

The information contained in this website is intended for healthcare professionals only.
Click “OK” if you are a healthcare professional.

OK